Idorsia
Elisabeth Gatineau is a seasoned professional in the pharmaceutical industry with extensive experience in regulatory writing and medical communications. Currently serving as Principal Medical Writer at Sobi - Swedish Orphan Biovitrum AB since January 2024, Elisabeth previously held the position of Associate Director - Expert Regulatory Writer at Idorsia Pharmaceuticals Ltd from 2020. With a career spanning over two decades at Novartis, roles included Senior Regulatory Writer, Expert Medical Writer, Senior Medical Writer, Senior Publishing Scientist, and Project Manager. Elisabeth's early career involved serving as Regulatory Affairs Manager at Novartis France from 1997 to 2000. Educational credentials include a Master's degree in Pharmaceutical Sciences from Université Claude Bernard Lyon 1, a Master's degree in Industrial and Physical Pharmacy and Cosmetic Sciences, and a Bachelor of Science in Analytical Chemistry, both from Paris-Sud University (Paris XI).
This person is not in any teams
This person is not in any offices
Idorsia
4 followers
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.